• Joaquim Barreto, Vaneza Wolf, Isabella Bonilha, Beatriz Luchiari, Marcus Lima, Alessandra Oliveira, Sofia Vitte, Gabriela Machado, Jessica Cunha, Cynthia Borges, Daniel Munhoz, Vicente Fernandes, Sheila Tatsumi Kimura-Medorima, Ikaro Breder, Marta Duran Fernandez, Thiago Quinaglia, Rodrigo B Oliveira, Fernando Chaves, Carlos Arieta, Gil Guerra-Júnior, Sandra Avila, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito, and Brazilian Heart Study Group.
• Atherosclerosis and Vascular Biology Laboratory (Atherolab), Cardiology Division, State University of Campinas (Unicamp), Sao Paulo, Brazil.
• Curr Med Res Opin. 2022 Apr 1; 38 (4): 523-529.

BackgroundOptimal control of traditional risk factors only partially attenuates the exceeding cardiovascular mortality of individuals with diabetes. Employment of machine learning (ML) techniques aimed at the identification of novel features of risk prediction is a compelling target to tackle residual cardiovascular risk. The objective of this study is to identify clinical phenotypes of T2D which are more prone to developing cardiovascular disease.MethodsThe Brazilian Diabetes Study is a single-center, ongoing, prospective registry of T2D individuals. Eligible patients are 30 years old or older, with a confirmed T2D diagnosis. After an initial visit for the signature of the informed consent form and medical history registration, all volunteers undergo biochemical analysis, echocardiography, carotid ultrasound, ophthalmologist visit, dual x-ray absorptiometry, coronary artery calcium score, polyneuropathy assessment, advanced glycation end-products reader, and ambulatory blood pressure monitoring. A 5-year follow-up will be conducted by yearly phone interviews for endpoints disclosure. The primary endpoint is the difference between ML-based clinical phenotypes in the incidence of a composite of death, myocardial infarction, revascularization, and stroke. Since June/2016, 1030 patients (mean age: 57 years, diabetes duration of 9.7 years, 58% male) were enrolled in our study. The mean follow-up time was 3.7 years in October/2021.ConclusionThe BDS will be the first large population-based cohort dedicated to the identification of clinical phenotypes of T2D at higher risk of cardiovascular events. Data derived from this study will provide valuable information on risk estimation and prevention of cardiovascular and other diabetes-related events.Clinicaltrials.Gov IdentifierNCT04949152.

17 keywords...

hide…